Giant Cell Arteritis (Temporal Arteritis)

Giant Cell Arteritis (Temporal Arteritis): A Clinical Compendium

Giant Cell Arteritis (GCA), historically referred to as Temporal Arteritis or Horton’s disease, represents a systemic granulomatous vasculitis of large and medium-sized arteries. Primarily affecting individuals over the age of 50, GCA is a medical emergency due to its high propensity for ischemic complications, most notably permanent vision loss. As a chronic inflammatory condition, it requires rapid identification, diagnostic confirmation, and long-term management strategies to prevent catastrophic vascular events.

1. Clinical Definition and Etiology

Definition

GCA is characterized by an inflammatory infiltration of the arterial wall, predominantly involving the branches of the external carotid artery (especially the temporal arteries). However, it is fundamentally a systemic pan-arteritis that can involve the aorta and its major branches, leading to aortic aneurysms and dissections.

Etiology and Pathogenesis

The etiology of GCA remains idiopathic, though current consensus points toward a complex interplay between genetic predisposition and environmental triggers.
* Genetic Factors: Strong associations exist with the HLA-DRB104 alleles.
* Environmental Triggers: Potential associations with infectious agents (e.g., Varicella-zoster virus) have been investigated, though no definitive pathogen has been identified.
* Immunological Mechanism:* The disease is mediated by T-cells (specifically CD4+ T-helper 1 and 17 cells) and macrophages. These cells infiltrate the arterial wall, producing cytokines (IL-6, IL-12, IL-18) that lead to the formation of multinucleated giant cells and the destruction of the internal elastic lamina.

2. Pathophysiology and Vascular Damage

The hallmark of GCA is the formation of granulomas within the tunica media of the arterial wall. This process follows a structured progression:

1. Dendritic Cell Activation: Resident dendritic cells in the adventitia are activated, recruiting T-cells and macrophages.
2. Cytokine Storm: Activated macrophages release proinflammatory cytokines and reactive oxygen species.
3. Intimal Hyperplasia: The inflammatory response triggers the proliferation of myofibroblasts in the intima, leading to luminal narrowing.
4. Ischemia: The combination of inflammation, edema, and intimal thickening causes critical stenosis or occlusion of the vessel, resulting in distal tissue ischemia.

3. Clinical Presentation and Staging

GCA presents with a constellation of systemic and local symptoms. Because the symptoms are often non-specific, clinicians must maintain a high index of suspicion in patients >50 years of age.

Standard Clinical Indicators

• Systemic: Fever, malaise, weight loss, anorexia, and night sweats.
• Cranial: New-onset localized headache (usually temporal), scalp tenderness (often noted when brushing hair), and jaw claudication (pain while chewing).
• Ocular: Transient monocular vision loss (amaurosis fugax), blurred vision, or sudden permanent blindness.
• Polymyalgia Rheumatica (PMR): Approximately 40-50% of GCA patients exhibit symptoms of PMR, characterized by proximal muscle pain and stiffness in the shoulders and hips.

The ACR Classification Criteria (1990)

A patient is considered to have GCA if at least 3 of the following 5 criteria are met:
1. Age at onset ≥ 50 years.
2. New headache.
3. Temporal artery abnormality (tenderness or decreased pulsation).
4. Elevated Erythrocyte Sedimentation Rate (ESR) ≥ 50 mm/hr.
5. Abnormal temporal artery biopsy (showing necrotizing arteritis with mononuclear cell infiltration or granulomatous process).

4. Differential Diagnosis

Distinguishing GCA from other conditions is vital, as the treatment involves high-dose corticosteroids which carry significant side effects.

• Infections: Occult bacterial or viral infections can mimic the systemic symptoms (fever, malaise).
• Malignancy: Lymphoma or occult solid tumors may present with elevated inflammatory markers and weight loss.
• Other Vasculitides: Takayasu arteritis (usually younger patients), Polyarteritis Nodosa (usually involves medium vessels, spares lungs).
• Ophthalmologic conditions: Acute angle-closure glaucoma or retinal artery occlusion.
• Neurological: Migraine or trigeminal neuralgia.

5. Diagnostic Testing Suite

Rapid diagnosis is mandatory to preserve sight.

Laboratory Markers

• ESR and CRP: These are highly sensitive but non-specific. An ESR < 40 mm/hr makes GCA less likely but does not rule it out.
• CBC: Often reveals normocytic anemia of chronic disease and thrombocytosis.

Imaging and Biopsy

• Temporal Artery Ultrasound (US): The "halo sign" (a hypoechoic rim around the artery) is highly specific for GCA.
• Temporal Artery Biopsy (TAB): The gold standard. A biopsy of at least 1–2 cm is required to account for "skip lesions," where inflammation is segmented rather than continuous.
• PET/CT or MRA: Increasingly used to evaluate extracranial (large vessel) GCA involvement, such as inflammation in the aorta or subclavian arteries.

6. Risks, Contraindications, and Management

Treatment Protocol

The cornerstone of GCA management is High-Dose Glucocorticoids.
* Initial Phase: Intravenous methylprednisolone (if visual symptoms are present) followed by high-dose oral prednisone (1 mg/kg/day).
* Maintenance: Tapering is gradual over 12–18 months.
* Adjuvant Therapy: Tocilizumab (an IL-6 receptor antagonist) is now FDA-approved for GCA, allowing for a "steroid-sparing" effect.

Risks and Side Effects of Treatment

Long-term corticosteroid use is associated with:
* Osteoporosis and bone fractures.
* Hypertension and hyperglycemia (diabetes).
* Increased susceptibility to infections.
* Psychiatric disturbances (mood swings, insomnia).
* Weight gain and fluid retention.

7. Prognosis and Long-term Monitoring

GCA is a chronic, relapsing-remitting condition. Long-term prognosis depends on early diagnosis and the prevention of permanent ischemic damage.
* Visual Prognosis: Once vision is lost, it is rarely recovered. Early steroid intervention is the only way to prevent progression to the second eye.
* Vascular Surveillance: Patients require long-term monitoring for the development of thoracic aortic aneurysms, which may present years after the initial diagnosis. Annual blood pressure checks and periodic imaging (MRI/CT) are recommended.

8. Frequently Asked Questions (FAQ)

1. Is Giant Cell Arteritis contagious?

No. GCA is an autoimmune inflammatory condition, not an infectious disease.

2. Can GCA be cured completely?

Most patients enter remission, but "cure" is not the typical term used. It is a chronic condition that requires careful monitoring for relapses, which occur in approximately 50% of patients.

3. What is the "halo sign" in ultrasound?

The halo sign is a dark, hypoechoic ring seen around the temporal artery during an ultrasound, representing wall edema and inflammation. It is a strong indicator of GCA.

4. Why is a biopsy necessary if blood tests are abnormal?

ESR and CRP are non-specific and can be elevated due to infection, malignancy, or other autoimmune diseases. A biopsy provides definitive histological proof of granulomatous vasculitis.

5. What are "skip lesions"?

GCA does not always affect the entire length of an artery. "Skip lesions" are segments of the artery that appear healthy between segments of active inflammation. This is why a long biopsy sample is required.

6. Can GCA cause strokes?

Yes. If the inflammatory process involves the intracranial arteries or the carotid arteries, it can lead to stenosis and subsequent ischemic stroke.

7. Does GCA always cause headaches?

No. While headaches are a classic symptom, some patients present only with systemic symptoms (fever, weight loss) or visual disturbances without significant head pain.

8. What is the role of Tocilizumab?

Tocilizumab blocks the IL-6 receptor, a key cytokine in GCA inflammation. It allows patients to taper off steroids faster, reducing the long-term side effects of prednisone.

9. How long do I need to take steroids?

Treatment typically lasts 12 to 18 months or longer. Tapering is individualized based on clinical symptoms and inflammatory markers (ESR/CRP).

10. Should I be worried about aortic aneurysms?

Yes. GCA increases the risk of aortic aneurysm and dissection. Patients should have regular chest imaging and blood pressure monitoring.

11. Is GCA hereditary?

While there is a genetic component (HLA-DRB1*04), it is not strictly hereditary, and most patients have no family history of the disease.

12. What should I do if I experience sudden vision loss?

This is a medical emergency. Go to the nearest Emergency Department immediately. Every minute counts in preventing permanent damage to the optic nerve.

Summary Table: Quick Reference for Clinicians

Disclaimer: This guide is intended for educational and informational purposes for healthcare professionals and students. It does not replace professional medical judgment, diagnosis, or treatment. Always consult clinical guidelines and institutional protocols for patient management.